Corporate Fact Sheet
Advancing Breakthrough Therapies for Cancer
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. In addition to one marketed product, we are advancing a deep product pipeline to address significant unmet medical needs.
ADCETRIS: First in a New Class of ADCs
Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs. In collaboration with Takeda Pharmaceutical Company Limited, it is commercially available in more than 65 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas, including Hodgkin lymphoma, cutaneous T-cell lymphoma, mature T-cell lymphomas and B-cell lymphomas.
Under the collaboration with Takeda, Seattle Genetics has full commercialization rights to ADCETRIS in the United States and Canada. Takeda has exclusive rights in all other countries.
SGN-CD33A: Pivotal Phase 3 Program
We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC that is being evaluated in the pivotal phase 3 CASCADE trial for acute myeloid leukemia (AML). AML is a significant unmet need, as treatments have not meaningfully changed in more than four decades.
ADCs: Integral Part of Cancer Therapy
ADCETRIS and 33A are two of more than 20 ADCs in clinical development using our proprietary technology, including more than 12 internal clinical and preclinical programs. We are advancing a deep product pipeline with opportunities across hematologic malignancies and solid tumors.
Our ADC technology also is employed by collaborators who are advancing multiple programs using Seattle Genetics’ proprietary approach to empowering antibodies. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.
Seattle Genetics was founded in 1998 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. We have more than 800 employees, all with a passion for helping people living with cancer.